BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19919912)

  • 1. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
    Kanitakis J; Baldassini S; Lora V; Euvrard S
    Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T1799A BRAF mutations in conjunctival melanocytic lesions.
    Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
    Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
    Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions.
    Saroufim M; Habib R; Karram S; Youssef Massad C; Taraif S; Loya A; Houreih MA; Sheikh SS; Amr SS; Satti M; Oberkanins C; Khalifeh I
    Am J Dermatopathol; 2014 Jan; 36(1):68-73. PubMed ID: 23782679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
    Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
    Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
    Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
    Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
    Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations in melanocytic tumors.
    Takata M; Saida T
    J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
    Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
    Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
    Takata M; Murata H; Saida T
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
    J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
    Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
    Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.